Utilizing MCID for evaluating clinical relevance of AD therapeutic interventions
Abstract With the recent approval of disease‐modifying treatments for mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) by the United States Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), European Medicine Agency's Committee for Medici...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2025-07-01
|
| coleção: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1002/trc2.70138 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|